



Published in final edited form as:

Annu Rev Neurosci. 2018 July 08; 41: 453–473. doi:10.1146/annurev-neuro-080317-061522.

Endogenous and Exogenous Opioids in Pain

Gregory Corder^{#1,2,3,4}, **Daniel C. Castro**^{#5}, **Michael R. Bruchas**^{5,6,7,8,9}, and **Grégory Scherrer**^{1,2,3,4,10}

¹Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Palo Alto, California 94304, USA; gs25@stanford.edu

²Department of Molecular and Cellular Physiology, Stanford University, Palo Alto, California 94304, USA

³Department of Neurosurgery, Stanford University, Palo Alto, California 94304, USA

⁴Stanford Neurosciences Institute, Palo Alto, California 94304, USA

⁵Department of Anesthesiology, Washington University in St. Louis, St. Louis, Missouri 63130, USA; bruchasm@wustl.edu

⁶Division of Basic Research, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63130, USA

⁷Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63130, USA

⁸Department of Neuroscience, Washington University School of Medicine, St. Louis, Missouri 63130, USA

⁹Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri 63130, USA

¹⁰New York Stem Cell Foundation - Robertson Investigator, Stanford University, Palo Alto, California 94304, USA

These authors contributed equally to this work.

Abstract

Opioids are the most commonly used and effective analgesic treatments for severe pain, but they have recently come under scrutiny owing to epidemic levels of abuse and overdose. These compounds act on the endogenous opioid system, which comprises four G protein-coupled receptors (mu, delta, kappa, and nociceptin) and four major peptide families (β -endorphin, enkephalins, dynorphins, and nociceptin/orphanin FQ). In this review, we first describe the functional organization and pharmacology of the endogenous opioid system. We then summarize current knowledge on the signaling mechanisms by which opioids regulate neuronal function and neurotransmission. Finally, we discuss the loci of opioid analgesic action along peripheral and

DISCLOSURE STATEMENT

G.S. is cofounder of Epiodyne, an opioid analgesic discovery company. M.R.B. is a cofounder of NeuroLux, a neuroscience technology company.

central pain pathways, emphasizing the pain-relieving properties of opioids against the affective dimension of the pain experience.

Keywords

opioid; analgesia; pain; signaling; neuroanatomy; perception

INTRODUCTION

Throughout human history, opioids have been used medicinally as an analgesic and recreationally as a euphorogenic. In the 1970s and 1980s, the efficacy of opioids to treat illness was vastly improved by advancements in modern medicinal chemistry and neuroscience. Specifically, the identification of the endogenous opioid peptides and receptors, accompanied by the development of new hyperselective and potent opioid drugs such as fentanyl and heroin, contributed both beneficial and detrimental effects on society and medicine. Today, opioids remain the mainstay analgesic treatment for severe acute, perioperative, and chronic pain. Paralleling the outstanding magnitude of pain in the United States (Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education 2011), the use of opioids for pain management has increased dramatically in the past two decades such that hydrocodone topped all prescriptions in 2011 (CDC 2013, Manchikanti et al. 2012). Unfortunately, opioids cause numerous detrimental effects, including analgesic tolerance, paradoxical hyperalgesia, nausea and vomiting, constipation, respiratory depression, and transition to addiction (Inturrisi 2002, Streicher & Bilsky 2017, Volkow & McLellan 2016). These side effects dramatically impact the quality of life of patients, and the number of deaths from opioid overdose now exceeds that of car accidents (CDC 2013). Elucidation of the neural mechanisms underlying opioid effects is urgently needed to develop innovative adjuvant therapies that dissociate opioid analgesia from side effects. In this review, we discuss the recent advancements made in understanding opioid mechanisms of function.

ENDOGENOUS OPIOID SYSTEM

Opioid Receptors

The endogenous opioid system comprises four seven-transmembrane G protein-coupled receptors (GPCRs): mu, delta, kappa, and nociceptin (MOPR, DOPR, KOPR, NOPR). Each receptor is encoded by a unique gene (*Oprm1*, *Oprd1*, *Oprk1*, *Oprl1*) but shares upward of 60% of its amino acid composition (Al-Hasani & Bruchas 2011, Kieffer & Evans 2009, Toll et al. 2016). Importantly, each receptor has a distinct expression pattern throughout the nervous system (Mansour et al. 1994, Neal et al. 1999). The recent crystal structures of all four receptors illustrate with unprecedented detail several similar molecular characteristics that may open new avenues for novel drug design (Granier et al. 2012, Manglik et al. 2012, Thompson et al. 2012, Wu et al. 2012). In particular, the crystal structures for the inactive state of each receptor have been identified (Figure 1a). These studies provided the first glimpse into atomic-level details of the receptors necessary for pinpointing the unique opioid binding pockets that maintain ligand preferences. For example, the active state of MOPR has

been crystalized with nanobodies to stabilize the structure; comparisons of the active and inactive states can identify potential sites of action for different molecules. A recent computational docking and drug design study, based on the active MOPR structure, was used to identify novel biased opioid analgesics (e.g., PZM21) that preferentially promote unique active-state conformations and signaling pathways (Manglik et al. 2016). In the case of NOPR, the least well understood of the opioid receptors, structural crystallization has indicated the lack of a salt bridge, which is common to the other receptors, resulting in an overall shift in the conformation of the fifth and sixth helices. This shift may be relevant for NOPR's lack of extracellular domain interactions with the other endogenous opioid ligands, which may be relevant for the development of receptor-specific drugs. Collectively, these results provide insight into how different agonists distinctly alter receptor conformations to direct downstream intracellular cascades, which may ultimately lead to more effective pharmacological treatments. Additionally, other mechanisms including alternative splicing and receptor interactions may contribute to the diversity of analgesic responses mediated by opioids (Fujita et al. 2015, Pasternak 2018, Samoshkin et al. 2015, Wieskopf et al. 2014).

Opioid Ligands

There are four major families of endogenous opioid ligands: β -endorphins, enkephalins, dynorphins, and nociceptin/orphanin FQ (Figure 1b). These opioid peptides along with their cognate receptors are widely expressed across the neuraxis and, in particular, pain pathways. In contrast to the amino acid or monoamine neurotransmitters, the opioid peptides are packaged into dense core vesicles in the soma and transported down to axon terminals. During this process, enzymatic splicing of the prepropeptides results in the formation of the diverse, receptor-specific peptide transmitters. The classic example of this process involves β -endorphin, the canonical μ -preferring ligand. β -Endorphin is cleaved from the parent molecule proopiomelanocortin (POMC), which is expressed in the arcuate nucleus and the nucleus of the solitary tract (Bloom et al. 1978, Lazarus et al. 1976). After packaging, POMC is cleaved into either proopiocorticotropin or adrenocorticotropin molecules, which are then again broken down into β -endorphin, α -melanocyte-stimulating hormone, and corticotropin-releasing hormone. These peptides act on MOPR, melanocortin, and corticotropin receptors, respectively. Additionally, 3-endorphin can be further cleaved into met-enkephalin, a nonselective agonist with affinity for both DOPR and MOPR.

Similar to β -endorphin, enkephalins and dynorphins arise from larger molecules that are broken down into more specific peptide transmitters. Preproenkephalin is cleaved into either met- or leu-enkephalin (Bower et al. 1976). Prodynorphin can be cleaved into several KOPR-selective ligands, including dynorphin-A[1-17], dynorphin-B[1-13], and α -neoendorphin. Further complicating the relationship between opioid receptors and their ligands, dynorphin can also be cleaved into less-opioid-selective leu-enkephalin or dynorphin-A[1-8], essentially making dynorphin a potential agonist for MOPRs, DOPRs, and KOPRs (Chavkin 2013, Goldstein et al. 1979). Last, nociceptin is derived from prepronociceptin and has a significantly higher affinity for NOPR than for the other opioid receptors (Meunier et al. 1995). This selectivity is likely due to the Phe amino acid in the first position of the nociceptin peptide sequence (James et al. 1982).

Contrasting with the tight, spatially controlled synaptic transmission of small-molecule transmitters such as glutamate or dopamine, opioids are thought to rely on volumetric release into synaptic and extrasynaptic spaces and diffuse toward their receptors (Banghart & Sabatini 2012, Duggan 2000). Indeed, electron microscopy illustrates that most MOPRs are extrasynaptic, being hundreds of microns away from release sites (Glass et al. 2009, Mansour et al. 1988, Svingos et al. 1996). That is, they are not found in the bed of symmetric or asymmetric synapses but rather shifted over, next to the synapse. Similarly, dynorphin release has been suggested to travel up to nearly 100 μm from the released terminal (Chavkin 2013, Drake et al. 1994), implying that opioid synapses may include a much broader area than typical fast transmitter synapses. The mechanisms that command the spatial and temporal dynamics of opioid release, and that direct peptides to these distant receptors, remain some of the biggest and exciting mysteries in the field.

SIGNALING

General Principles

Here, we briefly summarize the basic signaling properties of the four opioid receptors (Figure 2). Extensive reviews of opioid receptor signaling can be found elsewhere (Al-Hasani & Bruchas 2011, Lamberts & Traynor 2013, Toll et al. 2016, Williams et al. 2013). All four opioid receptors couple to the inhibitory G proteins ($G_{\alpha i}$ and $G_{\alpha o}$). Upon activation by agonists, either endogenous or exogenous, the G_{α} and $G_{\beta\gamma}$ subunits dissociate from one another and subsequently engage a variety of effectors and intracellular signaling cascades that typically depress neural functions. Note that MOPR, DOPR, and KOPR have been shown to signal through an agonist-independent mechanism called constitutive activity, including during persistent pain and stress (Corder et al. 2013, Polter et al. 2017, Yao et al. 2016). Although further *in vivo* studies are needed to understand the initiation mechanisms, constitutive activity of MOPR and DOPR is also observed after prolonged exogenous opioid stimulation (Liu & Prather 2001, Meye et al. 2012, Shoblock & Maidment 2006) and likely involves lowering the energy barrier to assume the active conformation, as predicted by the crystal structure (Manglik et al. 2012). Such activity might result from a variety of mechanisms, including changes in receptor density, changes in receptor phosphorylation, modulation of allosteric binding sites, or changes in interactions with accessory proteins such as β -arrestin and Src (Kenakin 2001, Walwyn et al. 2007).

Opioid receptor activity inhibits adenylate cyclase (AC), thereby reducing cyclic AMP production (Minneman & Iversen 1976), as evidence of pertussis toxin sensitivity was established in later experiments. Further studies revealed that guanine nucleotides such as GTP modulate agonist binding to opioid receptors in membrane preparations from brain tissue and that opioids stimulate GTPase activity (Barchfeld & Medzihradsky 1984, Childers & Snyder 1978). Beyond coupling to G_i and G_o proteins, all four opioid receptors engage other G proteins that modulate a multitude of effectors in addition to AC (Al-Hasani & Bruchas 2011, Toll et al. 2016, Williams et al. 2013).

Ion Channel Mechanisms

One of the most highly conserved pathways that opioid receptors use to alter neuronal function is the modulation of ion channels (Figure 2a). All four opioid receptors inhibit in N-, P/Q-, and L-type voltage-gated calcium channels (Rusin et al. 1997). This process, which occurs via the $G_{\beta\gamma}$ subunit inhibition of the channel, decreases the presynaptic calcium-dependent fusion of synaptic vesicles with the membrane terminal and subsequent neurotransmitter release. In dorsal root ganglion (DRG) neurons, N-type calcium channels along with opioid receptors can be co-internalized following prolonged agonist exposure, which may further reduce neurotransmitter release and the transmission of pain signals to the central nervous system (CNS) (Altier et al. 2006). Postsynaptically, opioids also cause a $G_{\beta\gamma}$ -mediated activation of G protein gated inwardly rectifying potassium (GIRK) channels (Torrecilla et al. 2002). This process is particularly important in postsynaptic compartments where dendritic hyperpolarization filters synaptic input. Mutant mice lacking GIRK channels, or expressing dysfunctional channels, show reduced opioid antinociception, establishing the importance of G protein-mediated potassium conductance modulation for opioid analgesia (Lujan et al. 2014, Nagi & Pineyro 2014).

Although the acute action of opioids on calcium and potassium channels typically reduces neurotransmission within seconds to minutes, chronic (hours to days) or abruptly interrupted opioid signaling can also facilitate excitatory synaptic plasticity. For example, withdrawal of exogenous opioids can elicit long-term potentiation (LTP) of synaptic transmission between primary afferent DRG nociceptors and second-order spinal cord neurons (Drdla et al. 2009, Zhou et al. 2010). This form of spinal LTP is considered a major substrate for opioid-induced hyperalgesia (OIH), a paradoxical decrease in pain threshold following opioid administration, and might also contribute to analgesic tolerance. The detailed molecular mechanisms underlying OIH and analgesic tolerance are not fully resolved, but they require presynaptic MOPRs in nociceptors (Corder et al. 2017) and involve the activation of microglia and molecules, including pannexin1, P2X4, and Toll-like receptors, that differentially contribute to OIH and tolerance in these cells (Burma et al. 2017, Trang et al. 2015). Finally, spinal LTP is also induced by peripheral injuries and represents a major mechanism of pathological pain. In this setting, a high dose of MOPR agonist can depotentiate synaptic transmission and erase spinal pain memory (Drdla-Schutting et al. 2012, Ruscheweyh et al. 2011).

Desensitization and Trafficking

Following activation, opioid receptors are phosphorylated by GPCR kinases, leading to β -arrestin 2 or 3 recruitment (Figure 2b). Arrestin molecules are key proteins that bind to phosphorylated GPCRs to regulate their G protein signaling through desensitization and internalization. The interaction of an opioid receptor with arrestin is thought to depend on the cellular context, agonist type, and model system studied. Importantly, mice that lack β -arrestin 2 show enhanced morphine antinociception and increased conditioned place preference (Bohn et al. 1999, 2003). Additionally, studies examining the aversive qualities of KOPR stimulation have shown that GRK3 knockout mice show no conditioned place aversion to KOPR agonists, and that phosphorylation of the receptor is required for these effects, implicating arrestin signaling in behavioral function (Bruchas et al. 2007a, 2011).

Remarkably, and contrary to previous models, internalized GPCRs are not inactive but may still signal, including from endosomal compartments (Eichel et al. 2016, Irannejad et al. 2013). These observations suggest, on the basis of the intracellular fate and signaling of internalized receptors (Bahouth & Nooh 2017, Irannejad & von Zastrow 2014), an additional level of complexity through which distinct ligands acting on the same opioid receptor can produce different cellular effects.

Arrestin Signaling

Whereas arrestin and opioid-receptor interactions were originally defined by their ability to regulate receptors, more recent studies have shown that arrestin is in fact a key signal effector at these receptors, mediating an array of cellular and behavioral responses. Phosphorylated arrestin-bound GPCR complexes recruit alternate, critically important downstream signaling cascades, including the mitogen-activated protein kinase (MAPK) cascade (Figure 2b). These MAPKs, which consist of three major proteins [extracellular signal regulated kinase 1 and 2 (ERK1/2), c-Jun N-terminal kinase 1–3 (JNK 1–3), and p38], notably modulate cell proliferation, differentiation, apoptosis, transcription factor regulation, ion channel regulation, neurotransmitter regulation, and protein scaffolding (Raman et al. 2007). MAPKs can regulate these effects over either short or long temporal domains to affect intra- and extracellular functions. All the opioid receptor subtypes stimulate phosphorylation of ERK 1/2, as well as JNK and p38 (Al-Hasani & Bruchas 2011, Bruchas et al. 2006, Chen et al. 2008, Eisinger & Ammer 2008, Macey et al. 2006). However, recent studies have reported that JNK phosphorylation by MOPR and KOPR can additionally engage noncanonical, arrestin-independent signaling pathways that inhibit G protein signaling at these receptors for long periods (Bruchas et al. 2007b, Melief et al. 2010, Schattauer et al. 2017).

Recent efforts have aimed to take advantage of the G protein versus arrestin signaling pathways by creating biased opioid receptor ligands. G protein-biased ligands could have fewer adverse effects, including constipation, respiratory depression, and even abuse liability (Brust et al. 2016, Manglik et al. 2016, Raehal et al. 2011, Schmid et al. 2017, Spangler & Bruchas 2017). However, the utility of biased agonists toward mitigating complex side effects, such as analgesic tolerance and OIH, remains controversial as numerous alternate signaling pathways and compensatory mechanisms are likely to be involved (Chen et al. 2016, Roedel et al. 2016). Finally, how these biased agonists work in vivo, within selected circuits, remains to be dissected.

NEUROANATOMICAL SUBSTRATES FOR OPIOID ANALGESIA

Somatosensory Neurons of the Dorsal Root Ganglia

A remarkable feature of opioid receptors is that they are present at virtually all neural loci contributing to the pain experience. Neurons of the DRG and trigeminal ganglia innervate peripheral organs and relay somatosensory information, including pain, to the spinal cord and medulla (Basbaum et al. 2009). All four opioid receptors are expressed by DRG somatosensory neurons (Arvidsson et al. 1995a,b; Zhu et al. 1998), and their activation by intradermal or intrathecal agonists produces antinociception (Chan et al. 2017, Gunther et al.

2017, Stein et al. 2009) (Figure 3a). Opioid receptor activation depresses glutamate and neuropeptide release from somatosensory afferents onto CNS neurons. Initial studies had suggested that the different types of opioid receptors, particularly MOPR and DOPR, were coexpressed by the same class of DRG neurons, namely unmyelinated peptidergic nociceptors. These neurons detect noxious stimuli in skin and internal organs and express the neuropeptides substance P and calcitonin gene-related protein (CGRP) and the heat-and capsaicin-sensitive transient receptor potential cation channel subfamily V member 1 (TRPV1) (Chen & Pan 2008, Ueda 2006, Vetter et al. 2006). MOPR expression in these cells is thought to contribute to the remarkable utility of mu agonists for perioperative pain management (Figure 2c). In recent years, this coexpression model has been reappraised following the emergence of novel techniques to investigate opioid receptor expression, particularly reporter mice expressing fluorescent opioid receptors and single-cell RNA sequencing (scRNA-seq) (Erbs et al. 2015, Scherrer et al. 2006, Usoskin et al. 2015). These studies suggest that each opioid receptor is differentially distributed among different DRG neuron classes, implying that receptor classes preferentially control distinct types of pain and somatosensory modalities. For example, delta opioid receptor-green fluorescent protein (DOR-GFP) knockin mouse line and scRNA-seq indicate that DOPR is enriched in myelinated mechanosensory neurons that project to the skin and that have been implicated in tactile hypersensitivity (allodynia) in the setting of chronic inflammatory or neuropathic pain (Bardoni et al. 2014, Scherrer et al. 2009, Usoskin et al. 2015). Note, however, that the expression pattern and function of DOPR in DRG remain debated and differ between species (Francois & Scherrer 2017, Gendron et al. 2015). MOPRs in DRG can be targeted by peripherally restricted agonists (i.e., limited blood-brain barrier permeability) to produce analgesia without CNS-derived side effects (DeHaven-Hudkins & Dolle 2004, Vadivelu et al. 2011). Recently, Spahn et al. (2017) refined this approach and developed an opioid analgesic with a low acid dissociation constant, such that this compound selectively activates MOPRs at acidic inflammation sites. Interestingly, however, studies using conditional knockout mice with a selective deletion of MOPRs in DRG nociceptors, but intact receptor expression in the CNS, showed that these MOPRs in DRG are not necessary for the antinociception resulting from systemic morphine (Corder et al. 2017, Weibel et al. 2013). Instead, MOPRs in DRG are important contributors to two of the adverse side effects associated with chronic MOPR agonist treatments, tolerance and OIH (Araldi et al. 2018, Corder et al. 2017; but see also Weibel et al. 2013). Other brain regions, including the periaqueductal gray and rostral ventromedial medulla, contribute to opioid analgesia, tolerance, and OIH (Connor et al. 2015, Eidson et al. 2013, Gaspari et al. 2018, Lane et al. 2005, Morgan et al. 2006, Vanderah et al. 2001, Wilson-Poe et al. 2017). However, activation of MOPR in peripheral nociceptor populations appears to be the key molecular event that initiates pathological plasticity within CNS pain circuits, thereby facilitating the onset of opioid antinociceptive tolerance, physical dependence, and the pronociceptive effects of opioids (Chu et al. 2008, Joseph et al. 2010, Kandasamy & Price 2015, Ossipov et al. 2005).

KOPR expression and function in DRG can now also be investigated with reporter mice (Cai et al. 2016, Liu-Chen 2017). Multiple preclinical studies provided evidence that KOPR in DRG may control visceral pain and suggested the use of peripherally restricted kappa

agonists for these types of pain (Kivell & Prisinzano 2010, Vanderah 2010). The function of NOPR in DRG is not well understood, but the recent generation of a NOPR-enhanced GFP (eGFP) receptor revealed a broad distribution of NOPR in DRG neurons, including in unmyelinated peptidergic nociceptors, and in several populations of myelinated neurons that may include cutaneous mechanoreceptors and proprioceptors (Ozawa et al. 2015).

Spinal Cord Dorsal Horn Circuits

Opioid receptors are expressed by second-order neurons of pain pathways (Figure 3b). MOPR has long been known to be expressed by nociceptive dorsal horn neurons, including excitatory interneurons and lamina I projection neurons of the anterolateral tract that relay nociceptive information to the lateral parabrachial nucleus, thalamus, and periaqueductal gray matter (Aicher et al. 2000, Spike et al. 2002). Immunohistochemical studies suggested that DOPR expression in the dorsal horn was restricted to primary afferent terminals (Dado et al. 1993), whereas DOR-GFP mice, as well as in situ hybridization and electrophysiological recordings in wild-type mice, support the idea that DOPR is expressed by multiple classes of spinal neurons (Wang et al. 2018). Specifically, DOPR expression in somatostatin-positive excitatory interneurons that gate mechanosensory inputs (Duan et al. 2014) contributes to the analgesic properties of DOR agonists. Additionally, DOPR and MOPR coexpression in projection neurons of the anterolateral tract (Wang et al. 2018) suggests that these two receptors may cooperate postsynaptically in cells receiving convergent inputs from segregated delta-positive and mu-positive afferents. The use of an antibody against the phosphorylated form of KOPR suggested expression of this receptor in inhibitory interneurons and spinal astrocytes (Xu et al. 2007), and electrophysiological recordings documented KOPR-selective, agonist U50488H-responsive neurons in the dorsal horn (Eckert & Light 2002). The development of reporter mice for KOPR, along with transcriptomic approaches, will enable the definitive identification of these neurons.

Dynorphin and enkephalin are expressed by distinct classes of dorsal horn interneurons (Boyle et al. 2017, Francois et al. 2017) and are upregulated in the spinal cord following peripheral injury to modulate chronic pain (Lai et al. 2008, Podvin et al. 2016, Xu et al. 2004). Additionally, recent evidence suggests that dynorphin, released by dorsal horn inhibitory interneurons, is an essential mediator of itch (Kardon et al. 2014). The NOPR-eGFP diffuse fluorescence signal throughout laminae I–III strongly suggests that NOPR may be expressed by dorsal horn neurons in addition to primary afferents (Ozawa et al. 2015), but the precise identity of these neurons, as well as the endogenous source of nociceptin peptide that acts on NOPR in laminae I–III, remains to be established. This identification of NOPR-expressing DRG and spinal neurons is likely to clarify the mechanisms by which NOPR agonists can facilitate or counteract mu-mediated antinociception (Toll et al. 2016).

Opioid Action in Brain Circuits for Pain Affect: Remodeling of Pain Percept

Painful experiences are both personal and complex; they are not linearly correlated to noxious input but rather are constructed from neural information relating sensory, emotional, interoceptive, inferential, and cognitive information, which coalesce into a unified perception of pain (Craig 2003, Wiech 2016).

A major site of action of mu opioid analgesics is the descending pain modulatory system, which includes the ventrolateral periaqueductal gray (vlPAG), rostral ventromedial medulla (RVM), and spinal cord (Basbaum & Fields 1984). Microinjection of mu opioids into the vlPAG, or the RVM, is sufficient to produce antinociception (al-Rodhan et al. 1992, Rossi et al. 1994). RVM neurons receive monosynaptic inputs from the vlPAG and have been categorized as on, off, or neutral cells on the basis of their action potential firing pattern, pronociceptive or antinociceptive properties, and response to opioids (Basbaum & Fields 1984, Cheng et al. 1986, Fang et al. 1989, Morgan et al. 1992). Mu opioids can inhibit on cells, and indirectly disinhibit off cells, to produce antinociception. Using endogenous opioids, genetic approaches have begun to molecularly identify RVM neuron subpopulations and clarify the synaptic mechanisms by which these neurons regulate pain thresholds at the spinal level. These studies showed that at least two populations of RVM GABAergic neurons project to the spinal cord and modulate pain (Figures 2c and 3b). The first population coexpresses preproenkephalin (Penk) and projects directly onto nociceptor terminals in the dorsal horns to inhibit pain (Zhang et al. 2015); they functionally correspond to off cells. In contrast, the second population, which expresses MOPRs, projects onto Penk-positive dorsal horn interneurons that then presynaptically inhibit mechanosensory neurons to facilitate mechanical pain (Francois et al. 2017).

Furthermore, rostral, subcortical, and cortical sites appear to be especially important for affective processing of pain, as well as the affective and rewarding aspects of pain analgesia (Cahill et al. 2013, Fields & Margolis 2015, Hummel et al. 2008, Kupers et al. 1991, Price et al. 1985) (Figure 3c). Clinical studies suggest that opioids produce pain relief by altering affective and somatic responses. For example, patient self-reports of morphine analgesia reveal that the sensation of pain is still present but affective aversive qualities are reduced (Price et al. 1985). Interestingly, this experience appears to be a dose-dependent pharmacological phenomenon, whereby progressively increasing doses of opioids diminishes first pain affect, then pain sensation (Cobos et al. 2012, LaGraize et al. 2006, Navratilova et al. 2015). Consistent with this, human functional MRI (fMRI) studies showed that much higher doses of opioids are required to reduce blood-oxygen-level-dependent activity in sensory brain regions than in limbic regions (Oertel et al. 2008).

Human positron emission tomography (PET) binding and fMRI studies of the anterior cingulate cortex (ACC) reveal that endogenous opioid release occurs during sustained pain experiences and largely correlates with analgesia against pain affect (Borras et al. 2004, Zubieta et al. 2005). This finding is also true for placebo analgesia (Bingel et al. 2006, Wager et al. 2007, Zubieta et al. 2005). Rodent models have further pinpointed the role of MOPR signaling in the ACC toward the relief of pain-induced aversion (LaGraize et al. 2006, Navratilova et al. 2015). Injection of naloxone, an opioid antagonist, into the ACC reduces the positive affect associated with pain relief, including by nonopioid analgesics, suggesting that endogenous opioids not only reduce nociceptive processes but also facilitate the reinforcing features of exogenous analgesia (Remeniuk et al. 2015). This feature of the endogenous opioid system is further supported by the result that MOPR blockade reduces dopamine release in the nucleus accumbens (NAc) that accompanies pain relief (Navratilova et al. 2012). Opioid analgesics thus act on multiple cortical and subcortical sites to influence dopaminergic neurotransmission between the ventral tegmental area (VTA) and NAc to

reduce pain aversion. Adding to this complexity, chronic pain is accompanied by changes in plasticity in the mesolimbic dopaminergic system. Inflammatory pain desensitizes MOPR in the VTA, promoting opioid consumption (Hipolito et al. 2015, Narita et al. 2005), and neuropathic pain is accompanied by decreased NAc dopamine release, an effect that involves microglial activation in the VTA (Taylor et al. 2015), as well as other negative regulators of dopamine transmission. Additionally, in the amygdala, a crucial node in affective brain circuits, MOPR is expressed by GABAergic neurons of the central nucleus and intercalated cell masses (Winters et al. 2017). Inhibition of these neurons by mu agonists may reduce aversive behavior and reduce amygdala inhibitory input onto descending brainstem pain pathway responses (Han et al. 2015, Namburi et al. 2015). Despite this progress, the precise aspects of the pain experience that are encoded in the NAc and amygdala (salience, valence, motivation, analgesia), and the identity of MOPR-expressing neurons that modulate pain in the ACC, NAc, amygdala, and VTA, remain to be determined.

KOPRs, DOPRs, and NOPRs also modulate pain supraspinally (Miaskowski et al. 1991, Yamamoto et al. 2001). KOPR activation in the dorsal raphe nucleus mediates descending antinociception (Land et al. 2009, Zhao et al. 2007). Additionally, the KOPR system gates affective information relating to stress and anxiety from the basolateral amygdala to the bed nucleus of the stria terminalis, as well as from inputs from the locus coeruleus (Crowley et al. 2016, McCall et al. 2017, Nygard et al. 2016). Although it is not yet fully understood for pain perception, the KOPR system is well positioned within the NAc circuitry to modify the hedonic value of nociceptive events and shape motivational behaviors in response to painful experiences (Al-Hasani et al. 2015, Castro & Berridge 2014, Negrete et al. 2017, Park et al. 2015). The dynorphin-kappa system regulates stress, aversion, mood, and relapse to drug-seeking for all major classes of abused drugs (Bruchas et al. 2010; Land et al. 2008, 2009) and may also contribute to shaping pain-induced negative affect (Massaly et al. 2017) and to driving comorbid depression and addiction. Interestingly, a recent study supports the idea that KOPR antagonists could be used to prevent stress-induced migraine (Xie et al. 2017). DOPRs and NOPRs are broadly expressed in pain affect and descending control circuits and are particularly enriched in the amygdala and ACC (Goody et al. 2002, Mansour et al. 1994, Ozawa et al. 2015, Scherrer et al. 2006, Toll et al. 2016); however, how these different receptor populations alter the different dimensions of pain experience requires further clarification.

CONCLUSIONS: DISSOCIATING DELETERIOUS SIDE EFFECTS FROM ANALGESIA

There are currently two main research paths to battle the opioid epidemic: discovering nonopioid analgesic therapies that could replace opioids or improving current opioid analgesics. For both paths, the complete resolution of opioid analgesics' mechanism of action, at the circuit, neural ensemble, synaptic, and molecular levels, will be a decisive step. For instance, the identification of MOPR-expressing neuronal populations in affective circuits that mediate opioid-induced reductions in pain affect will enable transcriptional and proteomic studies to uncover novel nonopioid analgesic targets. These studies are facilitated by the development of genetically engineered mouse lines for visualizing and manipulating

opioid receptor-expressing neurons (Cai et al. 2016, Erbs et al. 2015, Scherrer et al. 2006). Similar tools can now be used in vivo to study the cells that endogenously release enkephalins, dynorphins, endorphins, and nociceptin (Al-Hasani et al. 2015, Cowley et al. 2001, Francois et al. 2017).

By contrast, improving current opioid treatments requires an understanding of the mechanisms that underlie their deleterious side effects. At the cellular level, the development of conditional knockout mice lacking opioid receptors in defined cell types will greatly facilitate an understanding of the CNS structures that mediate OIH, antinociceptive tolerance, respiratory depression, and transition to addiction (Convertino et al. 2015, Corder et al. 2017, Gaveriaux-Ruff et al. 2011, Nygard et al. 2016, Weibel et al. 2013). At the level of signaling, biased agonists will clarify which signaling pathways need to be engaged to facilitate analgesia and limit deleterious effects such as respiratory depression, addiction, and constipation (Bohn & Aube 2017, Manglik et al. 2016, Schmid et al. 2017, Siuda et al. 2017, Spangler & Bruchas 2017). Collectively, this suite of novel genetic and pharmacological tools, together with the development of new behavioral paradigms for evaluating the pain experience and opioid analgesia in animal models (see the sidebar titled Translational Hurdles in Pain and Opioid Research), will likely yield insights into previously unanswerable questions. These advances are likely to lead to the development of more effective and safer analgesic treatments.

ACKNOWLEDGMENTS

We apologize to all investigators whose work could not be appropriately cited owing to space and citation limitations of this journal. This work was supported by National Institutes of Health grants R01DA044481 (G.S.), R01DA033396 (M.R.B.), K99DA043609 (G.C.), and F32DA043999 (D.C.C.). G.S. is a New York Stem Cell Foundation - Robertson Investigator. We thank Dr. Aashish Manglik for providing images of opioid receptor crystal structures (Figure 1).

LITERATURE CITED

- Aicher SA, Punnoose A, Goldberg A. 2000 μ -Opioid receptors often colocalize with the substance P receptor (NK1) in the trigeminal dorsal horn. *J. Neurosci.* 20:4345–54 [PubMed: 10818170]
- Al-Hasani R, Bruchas MR. 2011 Molecular mechanisms of opioid receptor-dependent signaling and behavior. *Anesthesiology* 115:1363–81 [PubMed: 22020140]
- Al-Hasani R, McCall JG, Shin G, Gomez AM, Schmitz GP, et al. 2015 Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward. *Neuron* 87:1063–77 [PubMed: 26335648]
- al-Rodhan NR, Yaksh TL, Kelly PJ. 1992 Comparison of the neurochemistry of the endogenous opioid systems in two brainstem pain-processing centers. *Stereotact. Funct. Neurosurg.* 59:15–19 [PubMed: 1295034]
- Altier C, Khosravani H, Evans RM, Hameed S, Peloquin JB, et al. 2006 ORL1 receptor-mediated internalization of N-type calcium channels. *Nat. Neurosci.* 9:31–40 [PubMed: 16311589]
- Araldi D, Khomula EV, Ferrari LF, Levine JD. 2018 Fentanyl induces rapid onset hyperalgesic priming: type I at peripheral and type II at central nociceptor terminals. *J. Neurosci.* 38:2226–45 [PubMed: 29431655]
- Arvidsson U, Dado RJ, Riedl M, Lee JH, Law PY, et al. 1995a delta-Opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. *J. Neurosci.* 15:1215–35 [PubMed: 7532700]

- Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, et al. 1995b Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. *J. Neurosci.* 15(5 Pt. 1):3328–41 [PubMed: 7751913]
- Bahouth SW, Nooh MM. 2017 Barcoding of GPCR trafficking and signaling through the various trafficking roadmaps by compartmentalized signaling networks. *Cell. Signal.* 36:42–55 [PubMed: 28449947]
- Banghart MR, Sabatini BL. 2012 Photoactivatable neuropeptides for spatiotemporally precise delivery of opioids in neural tissue. *Neuron* 73:249–59 [PubMed: 22284180]
- Barchfeld CC, Medzihradsky F. 1984 Receptor-mediated stimulation of brain GTPase by opiates in normal and dependent rats. *Biochem. Biophys. Res. Commun.* 121:641–48 [PubMed: 6145418]
- Bardoni R, Tawfik VL, Wang D, François A, Solorzano C, et al. 2014 Delta opioid receptors presynaptically regulate cutaneous mechanosensory neuron input to the spinal cord dorsal horn. *Neuron* 81:1312–27 [PubMed: 24583022]
- Basbaum AI, Bautista DM, Scherrer G, Julius D. 2009 Cellular and molecular mechanisms of pain. *Cell* 139:267–84 [PubMed: 19837031]
- Basbaum AI, Fields HL. 1984 Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. *Annu. Rev. Neurosci.* 7:309–38 [PubMed: 6143527]
- Bingel U, Lorenz J, Schoell E, Weiller C, Büchel C. 2006 Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. *Pain* 120:8–15 [PubMed: 16364549]
- Bloom FE, Rossier J, Battenberg EL, Bayon A, French E, et al. 1978 beta-endorphin: cellular localization, electrophysiological and behavioral effects. *Adv. Biochem. Psychopharmacol.* 18:89–109 [PubMed: 77124]
- Bohn LM, Aubé J. 2017 Seeking (and finding) biased ligands of the kappa opioid receptor. *ACS Med. Chem. Lett.* 8:694–700 [PubMed: 28740600]
- Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ, et al. 2003 Enhanced rewarding properties of morphine, but not cocaine, in β arrestin-2 knock-out mice. *J. Neurosci.* 23:10265–73 [PubMed: 14614085]
- Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. 1999 Enhanced morphine analgesia in mice lacking β -arrestin 2. *Science* 286:2495–98 [PubMed: 10617462]
- Borras MC, Becerra L, Ploghaus A, Gostic JM, DaSilva A, et al. 2004 fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. *J. Neurophysiol.* 91:2723–33 [PubMed: 15136603]
- Bower JD, Guest KP, Morgan BA. 1976 Enkephalin. Synthesis of two pentapeptides isolated from porcine brain with receptor-mediated opiate agonist activity. *J. Chem. Soc. Perkin Trans. 1* (23): 2488–92
- Boyle KA, Gutierrez-Mecinas M, Polgár E, Mooney N, O'Connor E, et al. 2017 A quantitative study of neurochemically defined populations of inhibitory interneurons in the superficial dorsal horn of the mouse spinal cord. *Neuroscience* 363:120–33 [PubMed: 28860091]
- Bruchas MR, Land BB, Aita M, Xu M, Barot SK, et al. 2007a Stress-induced p38 mitogen-activated protein kinase activation mediates K-opioid-dependent dysphoria. *J. Neurosci.* 27:11614–23 [PubMed: 17959804]
- Bruchas MR, Land BB, Chavkin C. 2010 The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. *Brain Res.* 1314:44–55 [PubMed: 19716811]
- Bruchas MR, Macey TA, Lowe JD, Chavkin C. 2006 Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. *J. Biol. Chem.* 281:18081–89 [PubMed: 16648139]
- Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, et al. 2011 Selective p38a MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. *Neuron* 71:498–511 [PubMed: 21835346]
- Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, et al. 2007b Long-acting κ opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. *J. Biol. Chem.* 282:29803–11

- Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, et al. 2016 Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. *Sci. Signal.* 9:ra117 [PubMed: 27899527]
- Burma NE, Bonin RP, Leduc-Pessah H, Baimel C, Cairncross ZF, et al. 2017 Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents. *Nat. Med.* 23:355–60 [PubMed: 28134928]
- Cahill CM, Xue L, Grenier P, Magnussen C, Lecour S, Olmstead MC. 2013 Changes in morphine reward in a model of neuropathic pain. *Behav. Pharmacol.* 24:207–13 [PubMed: 23591124]
- Cai X, Huang H, Kuzirian MS, Snyder LM, Matsushita M, et al. 2016 Generation of a KOR-Cre knockin mouse strain to study cells involved in kappa opioid signaling. *Genesis* 54:29–37 [PubMed: 26575788]
- Castro DC, Berridge KC. 2014 Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness “liking” and “wanting.” *J. Neurosci.* 34:4239–50 [PubMed: 24647944]
- CDC (Cent. Dis. Control Prev.). 2013 Vital signs: overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. *MMWRMorb. Mortal Wkly. Rep.* 62:537–42
- Chan HCS, McCarthy D, Li J, Palczewski K, Yuan S. 2017 Designing safer analgesics via μ -opioid receptor pathways. *Trends Pharmacol. Sci.* 38:1016–37 [PubMed: 28935293]
- Chavkin C 2013 Dynorphin—still an extraordinarily potent opioid peptide. *Mol. Pharmacol.* 83:729–36 [PubMed: 23152558]
- Chen G, Xie R-G, Gao Y-J, Xu Z-Z, Zhao L-X, et al. 2016 β -arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. *Nat. Commun.* 7:12531 [PubMed: 27538456]
- Chen L-Y, Huang J-X, Yu L-C. 2008 Involvement of ORL1 receptor and ERK kinase in the orphanin FQ-induced nociception in the nucleus accumbens of rats. *Regul. Pept.* 151:43–47 [PubMed: 18588920]
- Chen S-R, Pan H-L. 2008 Removing TRPV1-expressing primary afferent neurons potentiates the spinal analgesic effect of delta-opioid agonists on mechano-nociception. *Neuropharmacology* 55:215–22 [PubMed: 18579164]
- Cheng ZF, Fields HL, Heinricher MM. 1986 Morphine microinjected into the periaqueductal gray has differential effects on 3 classes of medullary neurons. *Brain Res.* 375:57–65 [PubMed: 3719359]
- Childers SR, Snyder SH. 1978 Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors. *Life Sci.* 23:759–61 [PubMed: 211364]
- Chu LF, Angst MS, Clark D. 2008 Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. *Clin. J. Pain* 24:479–96 [PubMed: 18574358]
- Cobos EJ, Ghasemlou N, Araldi D, Segal D, Duong K, Woolf CJ. 2012 Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia. *Pain* 153:876–84 [PubMed: 22341563]
- Connor M, Bagley EE, Chieng BC, Christie MJ. 2015 β -Arrestin-2 knockout prevents development of cellular μ -opioid receptor tolerance but does not affect opioid-withdrawal-related adaptations in single PAG neurons. *Br. J. Pharmacol.* 172:492–500 [PubMed: 24597632]
- Convertino M, Samoshkin A, Gauthier J, Gold MS, Maixner W, et al. 2015 μ -Opioid receptor 6-transmembrane isoform: a potential therapeutic target for new effective opioids. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 62:61–67 [PubMed: 25485963]
- Corder G, Doolen S, Donahue RR, Winter MK, Jutras BL, et al. 2013 Constitutive μ -opioid receptor activity leads to long-term endogenous analgesia and dependence. *Science* 341:1394–99 [PubMed: 24052307]
- Corder G, Tawfik VL, Wang D, Sypek EI, Low SA, et al. 2017 Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia. *Nat. Med.* 23:164–73 [PubMed: 28092666]
- Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, et al. 2001 Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. *Nature* 411:480–84 [PubMed: 11373681]

- Craig AD. 2003 A new view of pain as a homeostatic emotion. *Trends Neurosci.* 26:303–7 [PubMed: 12798599]
- Crowley NA, Bloodgood DW, Hardaway JA, Kendra AM, McCall JG, et al. 2016 Dynorphin controls the gain of an amygdalar anxiety circuit. *Cell Rep.* 14:2774–83 [PubMed: 26997280]
- Dado RJ, Law PY, Loh HH, Elde R. 1993 Immunofluorescent identification of a delta (delta)-opioid receptor on primary afferent nerve terminals. *Neuroreport* 5:341–44 [PubMed: 8298100]
- DeHaven-Hudkins DL, Dolle RE. 2004 Peripherally restricted opioid agonists as novel analgesic agents. *Curr. Pharm. Des.* 10:743–57 [PubMed: 15032700]
- Drake CT, Terman GW, Simmons ML, Milner TA, Kunkel DD, et al. 1994 Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. *J. Neurosci.* 14:3736–50 [PubMed: 7911518]
- Drdla R, Gassner M, Gingl E, Sandkühler J. 2009 Induction of synaptic long-term potentiation after opioid withdrawal. *Science* 325:207–10 [PubMed: 19590003]
- Drdla-Schutting R, Benrath J, Wunderbaldinger G, Sandkühler J. 2012 Erasure of a spinal memory trace of pain by a brief, high-dose opioid administration. *Science* 335:235–38 [PubMed: 22246779]
- Duan B, Cheng L, Bourane S, Britz O, Padilla C, et al. 2014 Identification of spinal circuits transmitting and gating mechanical pain. *Cell* 159:1417–32 [PubMed: 25467445]
- Duggan AW. 2000 Neuropeptide spread in the brain and spinal cord. *Prog. Brain Res.* 125:369–80 [PubMed: 11098673]
- Eckert WA, Light AR. 2002 Hyperpolarization of substantia gelatinosa neurons evoked by μ -, κ -, δ_1 -, and δ_2 -selective opioids. *J. Pain* 3:115–25 [PubMed: 14622798]
- Eichel K, Jullie D, von Zastrow M. 2016 β -Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. *Nat. Cell Biol.* 18:303–10 [PubMed: 26829388]
- Eisinger DA, Ammer H. 2008 δ -Opioid receptors activate ERK/MAP kinase via integrin-stimulated receptor tyrosine kinases. *Cell. Signal.* 20:2324–31 [PubMed: 18804531]
- Erbs E, Faget L, Scherrer G, Matifas A, Filliol D, et al. 2015 A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. *Brain Struct. Funct.* 220:677–702 [PubMed: 24623156]
- Fang FG, Haws CM, Drasner K, Williamson A, Fields HL. 1989 Opioid peptides (DAGO-enkephalin, dynorphin A(1–13), BAM 22P) microinjected into the rat brainstem: comparison of their antinociceptive effect and their effect on neuronal firing in the rostral ventromedial medulla. *Brain Res.* 501:116–28 [PubMed: 2572306]
- Fields HL, Margolis EB. 2015 Understanding opioid reward. *Trends Neurosci.* 38:217–25 [PubMed: 25637939]
- François A, Low SA, Sypek EI, Christensen AJ, Sotoudeh C, et al. 2017 A brainstem-spinal cord inhibitory circuit for mechanical pain modulation by GABA and enkephalins. *Neuron* 93:822–839.e6 [PubMed: 28162807]
- François A, Scherrer G. 2017 Delta opioid receptor expression and function in primary afferent somatosensory neurons. *Handb. Exp. Pharmacol.* doi: 10.1007/164_2017_58
- Fujita W, Gomes I, Devi LA. 2015 Heteromers of μ - δ opioid receptors: new pharmacology and novel therapeutic possibilities. *Br. J. Pharmacol* 172:375–87 [PubMed: 24571499]
- Gaspari S, Purushothaman I, Cogliani V, Sakloth F, Neve RL, et al. 2018 Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/ β -catenin pathway. *PNAS* 115:E2085–94 [PubMed: 29440403]
- Gaveriaux-Ruff C, Nozaki C, Nadal X, Hever XC, Weibel R, et al. 2011 Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. *Pain* 152:1238–48 [PubMed: 21295407]
- Gendron L, Mittal N, Beaudry H, Walwyn W. 2015 Recent advances on the δ opioid receptor: from trafficking to function. *Br. J. Pharmacol.* 172:403–19 [PubMed: 24665909]
- Glass MJ, Vanyo L, Quimson L, Pickel VM. 2009 Ultrastructural relationship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid receptor in the mouse central nucleus of the amygdala. *Neuroscience* 163:857–67 [PubMed: 19607886]

- Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. 1979 Dynorphin-(1–13), an extraordinarily potent opioid peptide. *PNAS* 76:6666–70 [PubMed: 230519]
- Goody RJ, Oakley SM, Filliol D, Kieffer BL, Kitchen I. 2002 Quantitative autoradiographic mapping of opioid receptors in the brain of δ -opioid receptor gene knockout mice. *Brain Res.* 945:9–19 [PubMed: 12113946]
- Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, et al. 2012 Structure of the δ -opioid receptor bound to naltrindole. *Nature* 485:400–4 [PubMed: 22596164]
- Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, et al. 2017 Targeting multiple opioid receptors—improved analgesics with reduced side effects? *Br. J. Pharmacol.* doi: 10.1111/bph.13809
- Han S, Soleiman MT, Soden ME, Zweifel LS, Palmiter RD. 2015 Elucidating an affective pain circuit that creates a threat memory. *Cell* 162:363–74 [PubMed: 26186190]
- Hipólito L, Wilson-Poe A, Campos-Jurado Y, Zhong E, Gonzalez-Romero J, et al. 2015 Inflammatory pain promotes increased opioid self-administration: role of dysregulated ventral tegmental area μ opioid receptors. *J. Neurosci.* 35:12217–31 [PubMed: 26338332]
- Hummel M, Lu P, Cummons TA, Whiteside GT. 2008 The persistence of a long-term negative affective state following the induction of either acute or chronic pain. *Pain* 140:436–45 [PubMed: 18945547]
- Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. 2011 *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.* Washington, DC: National Academies Press
- Inturrisi CE. 2002 Clinical pharmacology of opioids for pain. *Clin. J. Pain* 18(4 Suppl):S3–13 [PubMed: 12479250]
- Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, et al. 2013 Conformational biosensors reveal GPCR signalling from endosomes. *Nature* 495:534–38 [PubMed: 23515162]
- Irannejad R, von Zastrow M. 2014 GPCR signaling along the endocytic pathway. *Curr. Opin. Cell Biol.* 27:109–16 [PubMed: 24680436]
- James IF, Chavkin C, Goldstein A. 1982 Preparation of brain membranes containing a single type of opioid receptor highly selective for dynorphin. *PNAS* 79:7570–74 [PubMed: 6130527]
- Joseph EK, Reichling DB, Levine JD. 2010 Shared mechanisms for opioid tolerance and a transition to chronic pain. *J. Neurosci.* 30:4660–66 [PubMed: 20357116]
- Kandasamy R, Price TJ. 2015 The pharmacology of nociceptor priming. *Handb. Exp. Pharmacol.* 227:15–37 [PubMed: 25846612]
- Kardon AP, Polgar E, Hachisuka J, Snyder LM, Cameron D, et al. 2014 Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. *Neuron* 82:573–86 [PubMed: 24726382]
- Kenakin T 2001 Inverse, protean, and ligand-selective agonist: matters of receptor conformation. *FASEB J.* 3:593–611
- Kieffer BL, Evans CJ. 2009 Opioid receptors: from binding sites to visible molecules in vivo. *Neuropharmacology* 56(Suppl. 1):205–12 [PubMed: 18718480]
- Kivell B, Prisinzano TE. 2010 Kappa opioids and the modulation of pain. *Psychopharmacology* 210:109–19 [PubMed: 20372880]
- Kupers RC, Konings H, Adriaensen H, Gybels JM. 1991 Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. *Pain* 47:5–12 [PubMed: 1663226]
- LaGraize SC, Borzan J, Peng YB, Fuchs PN. 2006 Selective regulation of pain affect following activation of the opioid anterior cingulate cortex system. *Exp. Neurol.* 197:22–30 [PubMed: 15996657]
- Lai J, Luo M, Chen Q, Porreca F. 2008 Pronociceptive actions of dynorphin via bradykinin receptors. *Neurosci. Lett.* 437:175–79 [PubMed: 18450375]
- Lamberts JT, Traynor JR. 2013 Opioid receptor interacting proteins and the control of opioid signaling. *Curr. Pharm. Des.* 19:7333–47 [PubMed: 23448476]

- Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. 2008 The dysphoric component of stress is encoded by activation of the dynorphin K-opioid system. *J. Neurosci.* 28:407–14 [PubMed: 18184783]
- Land BB, Bruchas MR, Schattauer S, Giardino WJ, Aita M, et al. 2009 Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. *PNAS* 106:19168–73 [PubMed: 19864633]
- Lane DA, Patel PA, Morgan MM. 2005 Evidence for an intrinsic mechanism of antinociceptive tolerance within the ventrolateral periaqueductal gray of rats. *Neuroscience* 135:227–34 [PubMed: 16084660]
- Lazarus LH, Ling N, Guillemin R. 1976 beta-Lipotropin as a prohormone for the morphinomimetic peptides endorphins and enkephalins. *PNAS* 73:2156–59 [PubMed: 1064883]
- Liu JG, Prather PL. 2001 Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. *Mol. Pharmacol.* 60:53–62 [PubMed: 11408600]
- Liu-Chen L-Y. 2017 Characterization of a mutant mouse line expressing a fusion protein of kappa opioid receptor and tdTomato. Presented at the International Narcotics Research Conference, Chicago, July 9–14
- Luján R, Marron Fernandez de Velasco E, Aguado C, Wickman K. 2014 New insights into the therapeutic potential of GIRK channels. *Trends Neurosci.* 37:20–29 [PubMed: 24268819]
- Macey TA, Lowe JD, Chavkin C. 2006 Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons. *J. Biol. Chem.* 281:34515–24 [PubMed: 16982618]
- Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, et al. 2012 Opioid epidemic in the United States. *Pain Phys.* 15(3 Suppl):ES9–38
- Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, et al. 2012 Crystal structure of the μ -opioid receptor bound to a morphinan antagonist. *Nature* 485:321–26 [PubMed: 22437502]
- Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, et al. 2016 Structure-based discovery of opioid analgesics with reduced side effects. *Nature* 537:185–90 [PubMed: 27533032]
- Mansour A, Fox CA, Burke S, Meng F, Thompson RC, et al. 1994 Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. *J. Comp. Neurol.* 350:412–38 [PubMed: 7884049]
- Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. 1988 Anatomy of CNS opioid receptors. *Trends Neurosci.* 11:308–14 [PubMed: 2465635]
- Massaly N, Wilson-Poe A, Hipolito L, Markovic T, Bruchas MR, Moron J. 2017 Pain recruits accumbal kappa opioid system and alters opioid consumption. Presented at the International Narcotics Research Conference, Chicago, July 9–14
- McCall JG, Siuda ER, Bhatti DL, Lawson LA, McElligott ZA, et al. 2017 Locus coeruleus to basolateral amygdala noradrenergic projections promote anxiety-like behavior. *eLife* 6:e18247 [PubMed: 28708061]
- Melief EJ, Miyatake M, Bruchas MR, Chavkin C. 2010 Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. *PNAS* 107:11608–13 [PubMed: 20534436]
- Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, et al. 1995 Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. *Nature* 377:532–35 [PubMed: 7566152]
- Meye FJ, van Zessen R, Smidt MP, Adan RA, Ramakers GM. 2012 Morphine withdrawal enhances constitutive μ -opioid receptor activity in the ventral tegmental area. *J. Neurosci.* 32:16120–28 [PubMed: 23152596]
- Miaskowski C, Taiwo YO, Levine JD. 1991 Contribution of supraspinal μ - and δ -opioid receptors to antinociception in the rat. *Eur. J. Pharmacol.* 205:247–52 [PubMed: 1667910]
- Minneman KP, Iversen IL. 1976 Enkephalin and opiate narcotics increase cyclic GMP accumulation in slices of rat neostriatum. *Nature* 262:313–14 [PubMed: 183126]
- Morgan MM, Fossum EN, Levine CS, Ingram SL. 2006 Antinociceptive tolerance revealed by cumulative intracranial microinjections of morphine into the periaqueductal gray in the rat. *Pharmacol. Biochem. Behav.* 85:214–19 [PubMed: 16979226]

- Morgan MM, Heinricher MM, Fields HL. 1992 Circuitry linking opioid-sensitive nociceptive modulatory systems in periaqueductal gray and spinal cord with rostral ventromedial medulla. *Neuroscience* 47:863–71 [PubMed: 1579215]
- Nagi K, Pineyro G. 2014 Kir3 channel signaling complexes: focus on opioid receptor signaling. *Front. Cell Neurosci.* 8:186 [PubMed: 25071446]
- Namburi P, Beyeler A, Yorozu S, Calhoon GG, Halbert SA, et al. 2015A circuit mechanism for differentiating positive and negative associations. *Nature* 520:675–78 [PubMed: 25925480]
- Narita M, Kishimoto Y, Ise Y, Yajima Y, Misawa K, Suzuki T. 2005 Direct evidence for the involvement of the mesolimbic κ -opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. *Neuropsychopharmacology* 30:111–18 [PubMed: 15257306]
- Navratilova E, Xie JY, Meske D, Qu C, Morimura K, et al. 2015 Endogenous opioid activity in the anterior cingulate cortex is required for relief of pain. *J. Neurosci.* 35:7264–71 [PubMed: 25948274]
- Navratilova E, Xie JY, Okun A, Qu C, Eyde N, et al. 2012 Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry. *PNAS* 109:20709–13 [PubMed: 23184995]
- Neal CR, Mansour A, Reinscheid R, Nothacker HP, Civelli O, et al. 1999 Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with ^{125}I -[^{14}Tyr]-orphanin FQ binding. *J. Comp. Neurol.* 412:563–605 [PubMed: 10464356]
- Negrete R, García Gutierrez MS, Manzanares J, Maldonado R. 2017 Involvement of the dynorphin/KOR system on the nociceptive, emotional and cognitive manifestations of joint pain in mice. *Neuropharmacology* 116:315–27 [PubMed: 27567942]
- Nygaard SK, Hourguettes NJ, Sobczak GG, Carlezon WA, Bruchas MR. 2016 Stress-induced reinstatement of nicotine preference requires dynorphin/kappa opioid activity in the basolateral amygdala. *J. Neurosci.* 36:9937–48 [PubMed: 27656031]
- Oertel BG, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, et al. 2008 Differential opioid action on sensory and affective cerebral pain processing. *Clin. Pharmacol. Ther.* 83:577–88 [PubMed: 18030306]
- Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. 2005 Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. *Biopolymers* 80:319–24 [PubMed: 15795927]
- Ozawa A, Brunori G, Mercatelli D, Wu J, Cippitelli A, et al. 2015 Knock-in mice with NOP-eGFP receptors identify receptor cellular and regional localization. *J. Neurosci.* 35:11682–93 [PubMed: 26290245]
- Park PE, Schlosburg JE, Vendruscolo LF, Schulteis G, Edwards S, Koob GF. 2015 Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia. *Addict. Biol.* 20:275–84 [PubMed: 24330252]
- Pasternak GW. 2018 Mu opioid pharmacology: 40 years to the promised land. *Adv. Pharmacol.* 82:261–91 [PubMed: 29413524]
- Podvin S, Yaksh T, Hook V. 2016 The emerging role of spinal dynorphin in chronic pain: a therapeutic perspective. *Annu. Rev. Pharmacol. Toxicol.* 56:511–33 [PubMed: 26738478]
- Polter AM, Barcomb K, Chen RW, Dingess PM, Graziane NM, et al. 2017 Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress. *eLife* 6:e23785 [PubMed: 28402252]
- Price DD, Von der Gruen A, Miller J, Rafii A, Price C. 1985 A psychophysical analysis of morphine analgesia. *Pain* 22:261–69 [PubMed: 2993984]
- Raehal KM, Schmid CL, Groer CE, Bohn LM. 2011 Functional selectivity at the μ -opioid receptor: implications for understanding opioid analgesia and tolerance. *Pharmacol. Rev.* 63:1001–19 [PubMed: 21873412]
- Raman M, Chen W, Cobb MH. 2007 Differential regulation and properties of MAPKs. *Oncogene* 26:3100–12 [PubMed: 17496909]
- Remeniuk B, Sukhtankar D, Okun A, Navratilova E, Xie JY, et al. 2015 Behavioral and neurochemical analysis of ongoing bone cancer pain in rats. *Pain* 156:1864–73 [PubMed: 25955964]



- Roeckel L-A, Le Coz G-M, Gaveriaux-Ruff C, Simonin F. 2016 Opioid-induced hyperalgesia: cellular and molecular mechanisms. *Neuroscience* 338:160–82 [PubMed: 27346146]
- Rossi GC, Pasternak GW, Bodnar RJ. 1994 μ and δ opioid synergy between the periaqueductal gray and the rostro-ventral medulla. *Brain Res.* 665:85–93 [PubMed: 7882023]
- Ruscheweyh R, Wilder-Smith O, Drdla R, Liu X-G, Sandkuhler J. 2011 Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy. *Mol. Pain* 7:20 [PubMed: 21443797]
- Rusin KI, Giovannucci DR, Stuenkel EL, Moises HC. 1997 κ -Opioid receptor activation modulates Ca^{2+} currents and secretion in isolated neuroendocrine nerve terminals. *J. Neurosci.* 17:6565–74 [PubMed: 9254669]
- Samoshkin A, Convertino M, Viet CT, Wieskopf JS, Kambur O, et al. 2015 Structural and functional interactions between six-transmembrane μ -opioid receptors and β 2-adrenoreceptors modulate opioid signaling. *Sci. Rep.* 5:18198 [PubMed: 26657998]
- Schattauer SS, Land BB, Reichard KL, Abraham AD, Burgeno LM, et al. 2017 Peroxiredoxin 6 mediates $G_{\alpha i}$ protein-coupled receptor inactivation by cJun kinase. *Nat. Commun.* 8:743 [PubMed: 28963507]
- Scherrer G, Imamachi N, Cao Y-Q, Contet C, Mennicken F, et al. 2009 Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. *Cell* 137:1148–59 [PubMed: 19524516]
- Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Laustriat D, et al. 2006 Knockin mice expressing fluorescent δ -opioid receptors uncover G protein-coupled receptor dynamics in vivo. *PNAS* 103:9691–96 [PubMed: 16766653]
- Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, et al. 2017 Bias factor and therapeutic window correlate to predict safer opioid analgesics. *Cell* 171:1165–75
- Shoblock JR, Maidment NT. 2006 Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice. *Neuropsychopharmacology* 31:171–77 [PubMed: 15956992]
- Siuda ER, Carr R, Rominger DH, Violin JD. 2017 Biased μ -opioid receptor ligands: a promising new generation of pain therapeutics. *Curr. Opin. Pharmacol.* 32:77–84 [PubMed: 27936408]
- Spahn V, Del Vecchio G, Labuz D, Rodriguez-Gaztelumendi A, Massaly N, et al. 2017 A nontoxic pain killer designed by modeling of pathological receptor conformations. *Science* 355:966–69 [PubMed: 28254944]
- Spangler SM, Bruchas MR. 2017 Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits. *Curr. Opin. Pharmacol.* 32(Suppl. C):56–70 [PubMed: 27875804]
- Spike RC, Puskar Z, Sakamoto H, Stewart W, Watt C, Todd AJ. 2002 MOR-1-immunoreactive neurons in the dorsal horn of the rat spinal cord: evidence for nonsynaptic innervation by substance P-containing primary afferents and for selective activation by noxious thermal stimuli. *Eur. J. Neurosci.* 15:1306–16 [PubMed: 11994125]
- Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, et al. 2009 Peripheral mechanisms of pain and analgesia. *Brain Res. Rev.* 60:90–113 [PubMed: 19150465]
- Streicher JM, Bilsky EJ. 2017 Peripherally acting μ -opioid receptor antagonists for the treatment of opioid-related side effects: mechanism of action and clinical implications. *J. Pharm. Pract.* doi: 10.1177/0897190017732263
- Svingos AL, Moriwaki A, Wang JB, Uhl GR, Pickel VM. 1996 Ultrastructural immunocytochemical localization of μ -opioid receptors in rat nucleus accumbens: extrasynaptic plasmalemmal distribution and association with Leu5-enkephalin. *J. Neurosci.* 16:4162–73 [PubMed: 8753878]
- Taylor AMW, Castonguay A, Taylor AJ, Murphy NP, Ghogha A, et al. 2015 Microglia disrupt mesolimbic reward circuitry in chronic pain. *J. Neurosci.* 35:8442–50 [PubMed: 26041913]
- Thompson AA, Liu W, Chun E, Katritch V, Wu H, et al. 2012 Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. *Nature* 485:395–99 [PubMed: 22596163]
- Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT. 2016 Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. *Pharmacol. Rev.* 68:419–57 [PubMed: 26956246]

- Torrecilla M, Marker CL, Cintora SC, Stoffel M, Williams JT, Wickman K. 2002 G-protein-gated potassium channels containing Kir3.2 and Kir3.3 subunits mediate the acute inhibitory effects of opioids on locus ceruleus neurons. *J. Neurosci.* 22:4328–34 [PubMed: 12040038]
- Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM. 2015 Pain and poppies: the good, the bad, and the ugly of opioid analgesics. *J. Neurosci.* 35:13879–88 [PubMed: 26468188]
- Ueda H 2006 Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. *Pharmacol. Ther.* 109:57–77 [PubMed: 16023729]
- Usoskin D, Furlan A, Islam S, Abdo H, Lonnerberg P, et al. 2015 Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. *Nat. Neurosci.* 18:145–53 [PubMed: 25420068]
- Vadivelu N, Mitra S, Hines RL. 2011 Peripheral opioid receptor agonists for analgesia: a comprehensive review. *J. Opioid Manag.* 7:55–68 [PubMed: 21434585]
- Vanderah TW. 2010 Delta and kappa opioid receptors as suitable drug targets for pain. *Clin.J. Pain* 26(Suppl. 10):S10–15 [PubMed: 20026960]
- Vanderah TW, Suenaga NM, Ossipov MH, Malan TP, Jr., et al. 2001 Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. *J. Neurosci.* 21:279–86 [PubMed: 11150345]
- Vetter I, Wyse BD, Monteith GR, Roberts-Thomson SJ, Cabot PJ. 2006 The μ opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway. *Mol. Pain* 2:22 [PubMed: 16842630]
- Volkow ND, McLellan AT. 2016 Opioid abuse in chronic pain: misconceptions and mitigation strategies. *N. Engl. J. Med.* 374:1253–63 [PubMed: 27028915]
- Wager TD, Scott DJ, Zubieta J-K. 2007 Placebo effects on human μ -opioid activity during pain. *PNAS* 104:11056–61 [PubMed: 17578917]
- Walwyn W, Evans CJ, Hales TG. 2007 β -Arrestin2 and c-Src regulate the constitutive activity and recycling of μ opioid receptors in dorsal root ganglion neurons. *J. Neurosci.* 27:5092–104 [PubMed: 17494695]
- Wang D, Tawfik VL, Corder G, Low SA, Francois A, et al. 2018 Functional divergence of delta and mu opioid receptor organization in CNS pain circuits. *Neuron* 98(1):90–108.e5 [PubMed: 29576387]
- Weibel R, Reiss D, Karchewski L, Gardon O, Matifas A, et al. 2013 Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. *PLOS ONE* 8:e74706 [PubMed: 24069332]
- Wiech K 2016 Deconstructing the sensation of pain: the influence of cognitive processes on pain perception. *Science* 354:584–87 [PubMed: 27811269]
- Wieskopf JS, Pan YX, Marcovitz J, Tuttle AH, Majumdar S, et al. 2014 Broad-spectrum analgesic efficacy of IBNtxAis mediated by exon 11-associated splice variants of the mu-opioid receptor gene. *Pain* 155:2063–70 [PubMed: 25093831]
- Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, et al. 2013 Regulation of μ -opioid receptors: desensitization, phosphorylation, internalization, and tolerance. *Pharmacol. Rev.* 65:223–54 [PubMed: 23321159]
- Wilson-Poe AR, Jeong HJ, Vaughan CW. 2017 Chronic morphine reduces the readily releasable pool of GABA, a presynaptic mechanism of opioid tolerance. *J. Physiol.* 595:6541–55 [PubMed: 28815604]
- Winters BL, Gregoriou GC, Kisiwaa SA, Wells OA, Medagoda DI, et al. 2017 Endogenous opioids regulate moment-to-moment neuronal communication and excitability. *Nat. Commun.* 8:14611 [PubMed: 28327612]
- Wu H, Wacker D, Mileni M, Katritch V, Han GW, et al. 2012 Structure of the human κ -opioid receptor in complex with JDTic. *Nature* 485:327–32
- Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, et al. 2017 Kappa opioid receptor antagonists: a possible new class of therapeutics for migraine prevention. *Cephalalgia* 37:780–94 [PubMed: 28376659]


- Xu M, Bruchas MR, Ippolito DL, Gendron L, Chavkin C. 2007 Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by K opioid activation of p38 mitogen-activated protein kinase. *J. Neurosci.* 27:2570–81 [PubMed: 17344394]
- Xu M, Petraschka M, McLaughlin JP, Westenbroek RE, Caron MG, et al. 2004 Neuropathic pain activates the endogenous k opioid system in mouse spinal cord and induces opioid receptor tolerance. *J. Neurosci.* 24:4576–84
- Yamamoto T, Sakashita Y, Nozaki-Taguchi N. 2001 Antagonism of ORL1 receptor produces an algescic effect in the rat formalin test. *Neuroreport* 12:1323–27 [PubMed: 11388404]
- Yao X-Q, Malik RU, Griggs NW, Skjaerven L, Traynor JR, et al. 2016 Dynamic coupling and allosteric networks in the α subunit of heterotrimeric G proteins. *J. Biol. Chem.* 291:4742–53 [PubMed: 26703464]
- Zhang Y, Zhao S, Rodriguez E, Takatoh J, Han B-X, et al. 2015 Identifying local and descending inputs for primary sensory neurons. *J. Clin. Investig.* 25:3782–94
- Zhao Z-Q, Gao Y-J, Sun Y-G, Zhao C-S, Gereau RW, Chen Z-F. 2007 Central serotonergic neurons are differentially required for opioid analgesia but not for morphine tolerance or morphine reward. *PNAS* 104:14519–24 [PubMed: 17724336]
- Zhou HY, Chen SR, Chen H, Pan HL. 2010 Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. *J. Neurosci.* 30:4460–66 [PubMed: 20335482]
- Zhu Y, Hsu MS, Pintar JE. 1998 Developmental expression of the μ , κ , and δ opioid receptor mRNAs in mouse. *J. Neurosci.* 18:2538–49
- Zubieta J-K, Bueller JA, Jackson LR, Scott DJ, Xu Y, et al. 2005 Placebo effects mediated by endogenous opioid activity on μ -opioid receptors. *J. Neurosci.* 25:7754–62 [PubMed: 16120776]

TRANSLATIONAL HURDLES IN PAIN AND OPIOID RESEARCH

Current preclinical models of pain have elucidated detailed mechanisms for sensory detection and spinal encoding of nociceptive information. Unfortunately, a disconnect exists between clinical and preclinical assessments of pain: Human studies primarily use patient self-reports, whereas animal models typically use withdrawal reflexes or other indirect measures of pain. This raises the concern that animal models do not capture the holistic (i.e., sensory and affective) experience of pain in patients. This limitation has likely hampered the discovery of novel analgesic strategies to dampen pain negative affect in the clinic. Looking forward, efforts need to be directed toward dissecting the brain circuits of pain and require the development of measures of pain in animal models that more accurately reflect the in-the-moment and perceptual qualities of what it is like to experience pain. Tight modulation of neural circuits in vivo (e.g., optogenetic holography), paired with high-resolution, mesoscale monitoring of brain activity, may hold tremendous promise for determining how neural networks encode various dimensions of pain. Indeed, the combination of human functional imaging, behavior, and machine learning has already led to important advances in linking dynamic brain states to pain, thus paving a new avenue for preclinical research to follow in kind.

a Opioid receptor family**b** Endogenous opioid peptides**Figure 1.**

The endogenous opioid system. (a) Crystal structures of the inactive state of all four opioid receptors (DOPR, KOPR, NOPR, and MOPR). When an opioid agonist enters the binding pocket of its cognate receptor, a conformational change in the transmembrane domains allows for intracellular effector molecules to bind and activate signaling cascades that modulate neural function. The addition of stabilizing nanobodies to the crystal preparation has elucidated the active state of MOPR. Images courtesy of Dr. Aashish Manglik (UCSF) and used with his permission. (b) Chemical structures of the four main classes of opioid peptides: met-enkephalin, dynorphin-A, nociceptin, and β -endorphin. Abbreviations: DOPR, delta opioid receptor; KOPR, kappa opioid receptor; MOPR, mu opioid receptor; NOPR, nociceptin opioid receptor.

**Figure 2.**

Opioid modulation of signaling and synaptic transmission. (a) Presynaptic and postsynaptic effects of opioids on nociception. (Left) Noxious stimuli trigger action potential firing along DRG nociceptors. Upon reaching the synaptic terminal, VGCCs (yellow) open, facilitating neurotransmitter release. These neurotransmitters (e.g., glutamate) then open postsynaptic AMPA and NMDA receptors, which continue the nociceptive signals along pain circuits. (Right) Activation of opioid receptors promotes dissociation of inhibitory G_α and G_{βγ} protein subunits. G_α subunits suppress adenylate cyclase, and G_{βγ} subunits presynaptically inhibit VGCC opening and postsynaptically activate GIRK channels, resulting in reduced neurotransmitter release and membrane hyperpolarization, respectively. (b) Biased signaling pathways. Agonist binding to opioid receptors causes conformational changes that promote distinct recruitment of G protein and arrestin effector signaling cascades. While G proteins

mediate the inhibitory action of opioid signaling on neurotransmission, arrestin signaling is required both for internalization of opioid receptors and for kinase activities. The balance between G protein and arrestin signaling is thought, in part, to determine the analgesic versus detrimental effects of opioids. (c) Within pain circuits opioid receptors are activated by opioid analgesics such as enkephalin (endogenous) or morphine (exogenous). Endogenous opioids, such as enkephalins, can be released from infiltrating immune cells at the site of injuries and from neurons in the central nervous system. Abbreviations: AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; DRG, dorsal root ganglion; EPSC, excitatory postsynaptic current; ERK, extracellular signal regulated kinase; GIRK, G protein gated inwardly rectifying potassium; JNK, c-Jun N-terminal kinase; NMDA, *N*-methyl-D-aspartate; RVM, rostral ventromedial medulla; VGCC, voltage-gated calcium channel.




Figure 3. Neuroanatomical substrates of pain perception and remodeling by opioids. (a) A large interconnected neural network of supraspinal brain circuits transforms nociceptive information ascending from the spinal cord into an aversive, painful experience. (b) The opioid system is well positioned within this brain network to modify the perception of pain. The different opioid receptors and peptides are distinctively, though broadly, expressed in different sites, the function of which is under intense investigation. Relative opioid receptor (circles) and peptide (triangles) expression levels are denoted by the size of the shapes. (c,d)

Opioid receptor types and peptides are also distributed in distinct subpopulations of (c) DRG neurons, identified with the indicated markers such as TRPV1, and (d) second-order spinal cord dorsal horn neurons. NF marks large-diameter DRG neurons with myelinated axons. Striped neurons coexpress different opioid receptor types. Abbreviations: CGRP, calcitonin gene-related peptide; DRG, dorsal root ganglion; DOPR, delta opioid receptor; DYN, dynorphin; END, p-endorphin; ENK, enkephalin; KOPR, kappa opioid receptor; MOPR, mu opioid receptor; MrgD, Mas-related G protein-coupled receptor member D; NF, neurofilament; NOC, nociceptin/orphanin FQ; NOPR, nociceptin opioid receptor; Ret, Ret proto-oncogene; TrkC, tropomyosin receptor kinase C; TRPV1, transient receptor potential cation channel subfamily V member 1.